Tradestie Institutional Equity Comparison Engine

CYBN vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CYBN Overall Edge

CYBN Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cybin Inc. (CYBN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CYBN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, CYBN sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CYBN N/M vs BHST N/M Fwd P/E
Growth & Margin Winner CYBN
Op Margin 0.0% vs -18.0% ยท YoY +0.0% vs +3.8%
Momentum & Technical Winner CYBN
1Y -8.0% vs -79.4% ยท 52W Pos 59% vs 6%
Options & Structure Winner CYBN
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
CYBN NYSE American
Cybin Inc.
Pharmaceutical Preparations
$8.28
+1.22% 1D
Market Cap $413.4M
1M Return +50.27%
1Y Return -8.0%
Forward P/E N/M
Unified AI Score
63.8 / 100 BUY
Tech 75.0 Fund 66.0 Flow 58.0 Mom 70.0
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CYBN -8.0% BHST -79.4% Spread: +57.06 pp (CYBN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CYBN TTM Op. Margin: 0.0% BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CYBN vs BHST. Trailing 12-month operating profitability (CYBN 0.0% vs BHST -18.0%) and valuation multiples (CYBN N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CYBN (7) vs BHST (1)
Institutional Metric CYBN BHST Criterion Row Winner
Market Capitalization Scale $413.4M $29.9M Larger Scale CYBN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +3.8% Higher Growth BHST
Operating Margin (TTM) Profitability 0.0% -18.0% Higher Margin CYBN
Net Profit Margin Profitability 0.0% -31.2% Higher Margin CYBN
Return on Equity (ROE) Capital Efficiency -53.0% -142.5% Higher ROE CYBN
52-Week Range Position Momentum 59% ($5โ€“$11) 6% ($1โ€“$7) Stronger Trend CYBN
Beta / 30D Volatility Risk Regime 1.50ฮฒ ยท 54% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk CYBN
Unified Institutional Score Composite Signal 63.8 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite CYBN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CYBN vs BHST Buy Guide
CYBN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CYBN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CYBN nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.